Stockreport

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection [Yahoo! Finance]

Eledon Pharmaceuticals, Inc.  (ELDN) 
PDF th participant on March 23, 2024, in the Company's ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kid [Read more]